Clin Cancer Res 2006, 12: 4899–4907.CrossRefPubMed 4. Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol STA-9090 datasheet Exp Ther 2003, 307: 824–828.CrossRefPubMed 5. Dai H, AZD1480 research buy Marbach P, Lemaire

M, Hayes M, Elmquist WF: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003, 304: 1085–1092.CrossRefPubMed 6. Kil KE, Ding YS, Lin KS, Alexoff D, Kim SW, Shea C, Xu Y, Muench L, Fowler JS: Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 2007, 34: 153–163.CrossRefPubMed 7. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004, 64: 2333–2337.CrossRefPubMed 8. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K:

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104: 2940–2942.CrossRefPubMed 9. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH: The effect of Bcrp1 S63845 in vivo (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005, 65: 2577–2582.CrossRefPubMed

10. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001, 61: 3458–3464.PubMed 11. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A: Mechanisms of resistance to anticancer drugs: the role of the polymorphic Montelukast Sodium ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005, 6: 115–138.CrossRefPubMed 12. Sarkadi B, Homolya L, Szakacs G, Varadi A: Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006, 86: 1179–1236.CrossRefPubMed 13. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005, 4: 747–752.CrossRefPubMed 14.

Comments are closed.